Suppr超能文献

细胞减灭术(CS)联合腹腔内热化疗(HIPEC):术后进展、不良结局及围手术期危险因素

Cytoreductive Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Postoperative Evolution, Adverse Outcomes and Perioperative Risk Factors.

作者信息

Valencia-Sola Lucía, Becerra-Bolaños Ángel, Mateo-Ferragut María, Muiño-Palomar Virginia, Ojeda-Betancor Nazario, Rodríguez-Pérez Aurelio

机构信息

Department of Anesthesiology, Intensive Care and Pain Medicine, Hospital Universitario de Gran Canaria Doctor Negrín, 35010 Las Palmas de Gran Canaria, Spain.

Department of Medical and Surgical Sciences, Universidad de Las Palmas de Gran Canaria, 35001 Las Palmas de Gran Canaria, Spain.

出版信息

Healthcare (Basel). 2025 Apr 3;13(7):808. doi: 10.3390/healthcare13070808.

Abstract

Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) increases survival in peritoneal carcinomatosis, but complications may affect the long-term prognosis. We aimed to evaluate the postoperative evolution after CS + HIPEC, the appearance of adverse outcomes, and the associated risk factors. This was a retrospective observational study evaluating clinical practice in patients undergoing CS + HIPEC from 2016 to 2023 in a tertiary-level university hospital. The pre-, intra-, and postoperative variables were collected. The postoperative evolution, the appearance of postoperative complications, and the mortality were analyzed according to the perioperative data. In total, 62.3% of the patients developed some kind of complication. Renal failure was related to the length of surgery [mean difference (md) 111 min, 95% CI 11-210, = 0.029], postoperative vasoactive support [Odds Ratio (OR) 3.4, 95% CI 1.1-10.6, = 0.033], and non-invasive mechanical ventilation (OR 5.5, 95% CI 1.5-20.5, = 0.007). Respiratory failure was associated with renal replacement therapies (OR 13.8, 95% CI 1.3-143.9, = 0.006), postoperative creatinine (md 0.27 mg·dL, 95% CI 0.1-0.4, = 0.001), and C-reactive protein (md 33.5 mcg·L, 95% CI 0.1-66.8, = 0.049). Infectious complications were related to the length of surgery (md 84 min, 95% CI 12-156, = 0.024), non-invasive mechanical ventilation (OR 4.4, 95% CI 1.2-16.1, = 0.018), and renal replacement therapies (OR 11.6, 95% CI 1.1-119.6, = 0.012). The hospital stay was longer in patients with complications (md 14.8 ± 5.5 days, 95% CI 3.8-25.8, = 0.009). The mortality rate at 12 months was 15.6%. The mortality risk factors were the preoperative hemoglobin (md -1.7 g·dL, 95% CI -2.8--0.7, = 0.001) and creatinine (md -0.12 mg·dL, 95% CI -0.21--0.04, = 0.007) and the postoperative hemoglobin (md -1.15 g·dL, 95% CI 0.01-2.30, = 0.049) and C-reactive protein (md 54.6 mcg·L, 95% CI 18.5-90.8, = 0.004). Intraoperative epidural analgesia was found to be a protective factor for 12-month mortality (OR 0.25, 95% CI 0.07-0.90 = 0.027). A multivariate analysis performed after a univariate analysis showed that the only risk factor for overall mortality was not using intraoperative epidural analgesia. CS + HIPEC led to a high incidence of postoperative complications, but the occurrence of complications did not seem to affect postoperative survival.

摘要

细胞减灭术(CS)和腹腔内热灌注化疗(HIPEC)可提高腹膜癌病患者的生存率,但并发症可能影响长期预后。我们旨在评估CS + HIPEC术后的病情演变、不良结局的出现情况及相关危险因素。这是一项回顾性观察研究,评估了2016年至2023年在一家三级大学医院接受CS + HIPEC治疗的患者的临床实践情况。收集了术前、术中和术后变量。根据围手术期数据对术后病情演变、术后并发症的出现情况及死亡率进行了分析。总共有62.3%的患者出现了某种并发症。肾衰竭与手术时长相关[平均差(md)111分钟,95%置信区间(CI)11 - 210,P = 0.029]、术后血管活性药物支持[比值比(OR)3.4,95% CI 1.1 - 10.6,P = 0.033]以及无创机械通气(OR 5.5,95% CI 1.5 - 20.5,P = 0.007)。呼吸衰竭与肾脏替代治疗相关(OR 13.8,95% CI 1.3 - 143.9,P = 0.006)、术后肌酐水平(md 0.27 mg·dL,95% CI 0.1 - 0.4,P = 0.001)以及C反应蛋白水平(md 33.5 mcg·L,95% CI 0.1 - 66.8,P = 0.049)。感染性并发症与手术时长相关(md 84分钟,95% CI 12 - 156,P = 0.024)、无创机械通气(OR 4.4,95% CI 1.2 - 16.1,P = 0.018)以及肾脏替代治疗(OR 11.6,95% CI 1.1 - 119.6,P = 0.012)。出现并发症的患者住院时间更长(md 14.8 ± 5.5天,95% CI 3.8 - 25.8,P = 0.009)。12个月时的死亡率为15.6%。死亡危险因素为术前血红蛋白水平(md -1.7 g·dL,95% CI -2.8 - -0.7,P = 0.001)和肌酐水平(md -(此处原文有误,推测应为-)0.12 mg·dL,95% CI -0.21 - -0.04,P = 0.007)以及术后血红蛋白水平(md -1.15 g·dL,95% CI 0.01 - 2.30,P = 0.049)和C反应蛋白水平(md 54.6 mcg·L,95% CI 18.5 - 90.8,P = 0.004)。术中硬膜外镇痛被发现是12个月死亡率的一个保护因素(OR 0.25,95% CI 0.07 - 0.90,P = 0.027)。单因素分析后进行的多因素分析表明,总体死亡率的唯一危险因素是未使用术中硬膜外镇痛。CS + HIPEC导致术后并发症发生率较高,但并发症的发生似乎并未影响术后生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3030/11988831/bd06697413f6/healthcare-13-00808-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验